Advertisement

Osteoporosis International

, Volume 29, Issue 9, pp 2079–2086 | Cite as

Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case–control study

  • E. Losada
  • B. Soldevila
  • M.S. Ali
  • D. Martínez-Laguna
  • X. Nogués
  • M. Puig-Domingo
  • A. Díez-Pérez
  • D. MauricioEmail author
  • D. Prieto-Alhambra
Original Article

Abstract

Summary

We conducted a nested case–control study to study the association between antidiabetic treatments (alone or in combination) use and fracture risk among incident type 2 Diabetes mellitus patients. We found an increased risk of bone fracture with insulin therapy compared to metformin monotherapy.

Introduction

Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fragility fractures, to which antidiabetic therapies may contribute. We aimed to characterize the risk of fracture associated with different antidiabetic treatments as usually prescribed to T2DM patients in actual practice conditions.

Methods

A case–control study was nested within a cohort of incident T2DM patients registered in 2006–2012 in the Information System for Research Development in Primary Care (Catalan acronym, SIDIAP), a database which includes records for > 5.5 million patients in Catalonia (Spain). Each case (incident major osteoporotic fracture) was risk-set matched with up to five same-sex controls by calendar year of T2DM diagnosis and year of birth (± 10 years). Study exposure included previous use of all antidiabetic medications (alone or in combination), as dispensed in the 6 months before the index date, with metformin (MTF) monotherapy, the most commonly used drug, as a reference group (active comparator).

Results

Data on 12,277 T2DM patients (2049 cases and 10,228 controls) were analyzed. Insulin use was associated with increased fracture risk (adjusted OR 1.63 (95% CI 1.30–2.04)), as was the combination of MTF and sulfonylurea (SU) (adjusted OR 1.29 (1.07–1.56)), compared with MTF monotherapy. Sensitivity analyses suggest possible causality for insulin therapy but not for the MTF + SU combination association. No significant association was found with any other antidiabetic medications.

Conclusions

Insulin monotherapy was associated with an increased fracture risk compared to MTF monotherapy in T2DM patients. Fracture risk should be taken into account when starting a glucose-lowering drug as part of T2DM treatment.

Keywords

Epidemiology Fracture risk General population Type 2 diabetes mellitus 

Notes

Acknowledgments

This work has been carried out as a part of the PhD program of the Department of Medicine, Universitat Autònoma de Barcelona. CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM) is an initiative from Instituto de Salud Carlos III, Spain.

The authors thank Elaine Lilly, Ph.D., for revising the manuscript for English language usage.

Compliance with ethical standards

Conflict of interest

D.P.A. declares that his department/research group has received unrestricted research grants from Amgen, Servier Laboratoires, and Bioiberica; XN has been paid by Amgen and Lilly for developing and delivering educational presentations; D.M. declares receipt of honoraria from Abbott, Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Ferrer, GlaxoSmithKline, Eli Lilly, Medtronic, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi for consulting and presentations. ADP has been a speaker or advisory board member for Lilly, Amgen, GSK, and UCB and owns stocks of Active Life Scientific; E.L.G., B.S., M.S.A., M.P.D., and D.M.L. have no conflicts of interest.

References

  1. 1.
    Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292–1299CrossRefPubMedGoogle Scholar
  2. 2.
    Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495–505CrossRefPubMedGoogle Scholar
  3. 3.
    Martinez-Laguna D, Tebe C, Javaid MK, Nogues X, Arden NK, Cooper C, Diez-Perez A, Prieto-Alhambra D (2015) Incident type 2 diabetes and hip fracture risk: a population-based matched cohort study. Osteoporos Int 26:827–833CrossRefPubMedGoogle Scholar
  4. 4.
    Janghorbani M, Feskanich D, Willett WC, Hu F (2006) Prospective study of diabetes and risk of hip fracture: the nurses’ health study. Diabetes Care 29:1573–1578CrossRefPubMedGoogle Scholar
  5. 5.
    Melton LJ III, Leibson CL, Achenbach SJ, Therneau TM, Khosla S (2008) Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 23:1334–1342CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM (2011) Study of osteoporotic fractures (SOF) research group; osteoporotic fractures in men (MrOS) research group; health, aging, and body composition (health ABC) research group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184–2192CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, Yu Q, Zillikens MC, Gao X, Rivadeneira F (2012) Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol 27:319–332CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Farr JN, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S (2014) In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 29:787–795CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Saito M, Morume K (2013) Bone quality in diabetes. Front Endocrinol 4:72Google Scholar
  10. 10.
    van Daele PL, Tolk RP, Burger H, Algra D, Grobbee DE, Hofman A, Birkenhäger JC, Pols HA (1995) Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam study. Ann Intern Med 122:409–414CrossRefPubMedGoogle Scholar
  11. 11.
    Ivers RQ, Cumming RG, Mitchell P, Peduto AJ (2001) Diabetes and risk of fracture: the Blue Mountains eye study. Diabetes Care 24:1198–1203CrossRefPubMedGoogle Scholar
  12. 12.
    Yoshinari M, Wakisaka M, Nakamura U, Yoshioka M, Uchizono Y, Iwase M (2001) Orthostatic hypotension in patients with type 2 diabetes. Diabetes Care 24:1783–1786CrossRefPubMedGoogle Scholar
  13. 13.
    Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J (2012) Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab 14:634–643CrossRefPubMedGoogle Scholar
  14. 14.
    Oei L, Zillikens MC, Dehghan A, Buitendijk GH, Castaño-Betancourt MC, Estrada K, Stolk L, Oei EH, van Meurs JB, Janssen JA, Hofman A, van Leeuwen JP, Witteman JC, Pols HA, Uitterlinden AG, Klaver CC, Franco OH, Rivadeneira F (2013) High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam study. Diabetes Care 36:1619–1628CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    American Diabetes Association. Standards of Medical Care in Diabetes (2018) Diabetes Care 41:S1–S155CrossRefGoogle Scholar
  16. 16.
    Vestergaard P, Rejnmark L, Mosekilde L (2009) Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 84:45–55CrossRefPubMedGoogle Scholar
  17. 17.
    Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G (2008) Diabetes outcome progression trial (ADOPT) study group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 31:845–851CrossRefPubMedGoogle Scholar
  18. 18.
    Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F, Chiasserini V, Marchionni N, Rotella CM (2008) Bone fractures and hypoglycemic treatment in type 2 diabetic patients. Diabetes Care 31:199–203CrossRefPubMedGoogle Scholar
  19. 19.
    Bilik D, McEwen LN, Brown MB, Pomeroy NE, Kim C, Asao K, Crosson JC, Duru OK, Ferrara A, Hsiao VC, Karter AJ, Lee PG, Marrero DG, Selby JV, Subramanian U, Herman WH (2010) Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 95:4560–4565CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM (2009) Thiazolidinediones and fractures in men and women. Arch Intern Med 169:1395–1402CrossRefPubMedGoogle Scholar
  21. 21.
    Loke YK, Singh S, Furberg CD (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analyses. CMAJ 180:32–39CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Starup-Linde J, Gregersen S, Frost M, Vestergaard P (2017) Use of glucose-lowering drugs and risk of fracture in patients with type 2 diabetes. Bone 95:136–142CrossRefPubMedGoogle Scholar
  23. 23.
    Rajpathak SN, Fu C, Brodovicz KG, Engel SS, Lapane K (2015) Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes. Drugs Aging 32:321–327CrossRefPubMedGoogle Scholar
  24. 24.
    Losada-Grande E, Hawley S, Soldevila B, Martinez-Laguna D, Nogues X, Diez-Perez A, Puig-Domingo M, Mauricio D, Prieto-Alhambra D (2017) Insulin use and excess fracture risk in patients with type 2 diabetes: a propensity-matched cohort study. Sci Rep 7:3781CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mabilleau G, Mieczowska A, Chappard D (2014) Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes 6:260–266CrossRefPubMedGoogle Scholar
  26. 26.
    Driessen JH, de Vries F, van Onzenoort H, Harvey NC, Neef C, van den Bergh JP, Vestergaard P, Henry RM (2017) The use of incretins and fractures—a meta-analysis on population-based real-life data. Br J Clin Pharmacol 83:923–926CrossRefPubMedGoogle Scholar
  27. 27.
    Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J (2015) Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine 48:107–115CrossRefPubMedGoogle Scholar
  28. 28.
    Monami M, Dicembrini I, Antenore A, Mannucci E (2011) Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 34:2474–2476CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Garcia-Gil M, Hermosilla E, Prieto-Alhambra D, Fina D, Rosell M, Ramos R, Rodriguez J, Williams T, Van Staa T, Bolívar B (2011) Construction and validation of scoring a system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 19:135–145Google Scholar
  30. 30.
    Pagès-Castellà A, Carbonell-Abella C, Avilés FF, Alzamora M, Baena-Díez JM, Laguna DM, Nogués X, Díez-Pérez A, Prieto-Alhambra D (2012) Burden of osteoporotic fractures in primary health care in Catalonia (Spain) a population-based. BMC Musculoskelet Disord 13:79CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Domíngeux-Berjón MF, Borrell C, Cano-Serral G, Esnaola S, Nolasco A, Pasarín MI, Ramis R, Saurina C, Escolar-Pujolar A (2008) Constructing a deprivation index based on census data in large Spanish cities (the MEDEA project). Gac Sanit 22:179–187CrossRefGoogle Scholar
  32. 32.
    Gilbert MP, Pratley RE (2015) The impact of diabetes and diabetes medications on bone health. Endocr Rev 36:194–213CrossRefPubMedGoogle Scholar
  33. 33.
    Srikanthan P, Crandall CJ, Miller-Martinez D, Seeman TE, Greendale GA, Binkley N, Karlamangla AS (2014) Insulin resistance and bone strength findings from the study of midlife in the United States. J Bone Miner Res 29:796–803CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mauricio D, Meneghini L, Seufert J, Liao L, Wang H, Tong L, Cali A, Stella P, Carita P, Khunti K (2017) Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab 19:1155–1164CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Overbeek JA, Heintjes EM, Prieto-Alhambra D, Blin P, Lassalle R, Hall GC, Lapi F, Bianchini E, Hammar N, Bezemer ID, Herings RMC (2017) Type 2 diabetes mellitus treatment patterns across Europe: a population-based multi database study. Clin Ther 39:759–770CrossRefPubMedGoogle Scholar
  36. 36.
    Mata-Cases M, Franch-Nadal J, Real J, Mauricio D (2016) Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007–2013 in Catalonia: a population-based study. BMJ Open 6:e012463CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW, TECOS Study Group (2017) Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial. Diabetes Obes Metab 19:78–86CrossRefPubMedGoogle Scholar
  38. 38.
    Mosenzon O, ei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A, Hirshberg B, Cahn A, Stahre C, Strojek K, Bhatt DL, Raz I (2015) Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial. Diabetes Care 38:2142–2150CrossRefPubMedGoogle Scholar
  39. 39.
    Martínez-Laguna D, Soria-Castro A, Carbonell-Abella C, Orozco-López P, Estrada-Laza P, Conesa-García A et al (2014) P-58: Estudio de incidencia de fracturas por fragilidad registradas en pacientes atendidos en la Atención Primaria de salud. Rev Osteoporos Metab Min 6:36–44Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  • E. Losada
    • 1
    • 2
  • B. Soldevila
    • 3
    • 4
    • 5
  • M.S. Ali
    • 6
    • 7
  • D. Martínez-Laguna
    • 8
    • 9
    • 10
  • X. Nogués
    • 10
    • 11
  • M. Puig-Domingo
    • 2
    • 3
    • 4
    • 5
  • A. Díez-Pérez
    • 10
    • 11
  • D. Mauricio
    • 2
    • 3
    • 4
    • 5
    Email author
  • D. Prieto-Alhambra
    • 6
    • 8
    • 10
  1. 1.Department of Endocrinology and NutritionHospital Can MissesEivissaSpain
  2. 2.Department of MedicineUniversitat Autònoma de BarcelonaBarcelonaSpain
  3. 3.Department of Endocrinology and NutritionHospital Universitari Germans Trias i PujolBarcelonaSpain
  4. 4.Fundació Institut d’Investigació Germans Trias i PujolUniversitat Autònoma de BarcelonaBarcelonaSpain
  5. 5.CiBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)Instituto de Salud Carlos IIIMadridSpain
  6. 6.Musculoskeletal Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMSUniversity of OxfordOxfordUK
  7. 7.Faculty of Epidemiology and Population Health, Department of Infectious Disease EpidemiologyLondon School of Hygiene and Tropical MedicineLondonUK
  8. 8.GREMPAL Research Group, IDIAP Jordi GolUniversitat Autònoma de BarcelonaBarcelonaSpain
  9. 9.Primary Care BarcelonaInstitut Català de la SalutBarcelonaSpain
  10. 10.CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES)Instituto de Salud Carlos IIIMadridSpain
  11. 11.Department of Internal MedicineHospital del Mar, Universitat Autònoma de BarcelonaBarcelonaSpain

Personalised recommendations